1	Full Title: Risk of Incident Atrial Fibrillation in Women with a History of Hypertensive
2	Disorders of Pregnancy: A Population-Based Retrospective Cohort Study
3	Short Title: AFib Risk Following Pregnancy Hypertension
4	
5	Authors: Amy Johnston, PhD, CPH ^{1,2} ; William Petrcich, MSc ³ ; Graeme N. Smith, MD
6	PhD ⁴ ; Deshayne B. Fell, PhD ^{1,5} ; Peter Tanuseputro, MD MHSc ⁶ ; Thais Coutinho, MD ^{7*} ;
7	Jodi D. Edwards, PhD ^{1-3*}
8	
9	¹ School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario,
10	Canada
11	² Brain and Heart Nexus Research Program, University of Ottawa Heart Institute, Ottawa,
12	Ontario, Canada
13	³ ICES, Ottawa, Ontario, Canada
14	⁴ Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Kingston
15	Health Sciences Centre, Queens University, Kingston, Ontario, Canada
16	⁵ Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
17	⁶ Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The
18	University of Hong Kong, Hong Kong SAR, China
19	⁷ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
20	
21	* Drs. Coutinho and Edwards share senior authorship of this manuscript.
22	
23	

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

24 Corresponding Authors:

- 25 Dr. Thais Coutinho
- 26 Mayo Clinic
- 27 Department of Cardiovascular Medicine
- 28 200 First St. SW
- 29 Rochester, Minnesota, United States 55905
- 30 E-mail: coutinho.thais@mayo.edu
- 31
- 32 Dr. Jodi Edwards
- 33 University of Ottawa Heart Institute
- 34 H4100 40 Ruskin Street
- 35 Ottawa, Ontario, Canada K1Y 4W7
- 36 E-mail: <u>JEdwards@ottawaheart.ca</u>
- 37
- 38 Total word count (excluding Title Page, Abstract, References, Tables and Figures
- 39 Legends, Acknowledgements, & Disclosures): 5,242

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

41 Abstract

Background: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as cardiovascular disease (CVD) later in life. Despite the robust association between hypertension and atrial fibrillation (AFib), comparatively little is known about HDP and individual HDP subtypes as sex-specific risk factors for AFib.

47

48 Methods: A population-based retrospective cohort study of 771,521 nulliparous women 49 discharged for obstetrical delivery of their first live or stillborn singleton infant between 50 2002-2017 in Ontario, Canada. Data were obtained from record-level, coded, and linked 51 population-based administrative databases housed at ICES. Using competing risks Cox 52 proportional hazards regression, we estimated crude and multivariable-adjusted cause-53 specific hazard ratios (csHRs) and 95% confidence intervals (CIs) for associations 54 between history of any HDP-and its six subtypes-and AFib before death, as well as all-55 cause mortality without a prior AFib diagnosis.

56

Results: Approximately 8% of subjects were diagnosed with HDP during the 16-year exposure accrual period. The total person-time of follow-up was 7,380,304 person-years, during which there were 2,483 (0.3%) incident AFib diagnoses and 2,951 (0.4%) deaths. History of any HDP was associated with an increased csHazard of both incident AFib and death without a prior AFib diagnosis [adjusted csHRs (95% Cls): 1.45 (1.28-1.64) and 1.31 (1.16-1.47), respectively]. These associations were observed in relatively young women (median time-to-event: 7 years postpartum). Associations suggestive of a 'dose-

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

64	response' relationship were also observed, whereby both HDP severity, and presence of
65	pre-pregnancy chronic hypertension, were associated with higher rates of both outcomes.
66	
67	Conclusions: People exposed to HDP in their first delivery have a significantly increased
68	csHazard of incident AFib compared to their unexposed counterparts, with higher rates
69	observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic
70	hypertension in pregnancy. Given the substantial morbidity and mortality burden of AFib
71	in women, these findings underscore the critical importance of considering history of HDP
72	in risk calculation/stratification for both arrhythmic and non-arrhythmic CVDs; improving
73	population-based surveillance of traditional and female-specific CVD risk factors; and
74	developing targeted prevention strategies aimed at reducing the occurrence and burden
75	of HDP.
76	
77	Keywords: Hypertensive disorders of pregnancy, atrial fibrillation, retrospective cohort,
78	administrative data, cardio-obstetrics
79	
80	
81	
82	

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

84 Clinical Perspective

85 What is new?

- In this population-based retrospective cohort study of 771,521 nulliparous women,
- 87 a history of hypertensive disorders of pregnancy (HDP) significantly increased the 88 cause-specific hazard of incident atrial fibrillation (AFib) compared to women 89 without HDP, even after adjustment for confounders, and this association was
- 90 observed in relatively young women (median follow-up: 7 years postpartum).
- Associations suggestive of a 'dose-response' relationships were observed,
 whereby subjects with more severe *de novo* HDP diagnoses, as well as those with
 pre-pregnancy chronic hypertension, had higher cause-specific rates of AFib, with
 the highest rate observed in subjects exposed to chronic hypertension in
 pregnancy.
- 96

97 What are the clinical implications?

- These findings suggest that women with a history of any HDP–especially those
 with pre-pregnancy chronic hypertension–may benefit from closer monitoring for
 the early detection of AFib.
- Enhanced population-based surveillance of, and targeted strategies to prevent,
 HDP as a female-specific cardiovascular risk factor are needed to mitigate
 intermediate- and long-term cardiovascular disease risk associated with these
 adverse pregnancy conditions.
- 105
- 106
- 107

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

108 Introduction

Hypertensive disorders of pregnancy (HDP), which affect between 5 to 15% of all pregnancies,^{1, 2} are a heterogeneous group of obstetrical complications with differing epidemiology, pathophysiology, and symptomatology.³ They are a major cause of maternal and fetal/neonatal morbidity and mortality,⁴ with several studies reporting associations between a history of HDP and acute cardiac events in the peripartum period, as well as cardiovascular disease (CVD), later in life.^{5, 6}

115

The pathophysiological mechanisms linking HDP and CVD remain unclear.⁷ However, observed associations may be driven by an interplay of several pregnancy-related factors that act through both maternal (e.g., advanced maternal age, history of obstetrical complications) and placental pathways, combined with additional accumulated exposure to non-pregnancy-related risk factors over the life course.⁷ HDP may also trigger or accelerate vascular ageing,⁸ which could also contribute to existing pathological processes, or may itself be a driving mechanism for increased CVD risk.⁴

123

Most published studies assessing CVD risk in people with a history of HDP have focused on non-arrhythmic cardiovascular outcomes (e.g., myocardial infarction, stroke, heart failure, and coronary artery disease).^{7, 9, 10} However, the global prevalence of atrial fibrillation (AFib) has rapidly increased over the past three decades,¹¹ rising from 19 million individuals in 1990 to 38 million in 2017 (100% increase).¹¹ Indeed, AFib is now considered the cardiovascular epidemic of the 21st century,¹² with the absolute burden of

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- the disease projected to rise by more than 60% by 2025,¹² underscoring the critical need
 to study AFib to better understand its unique risk factors.
- 132

Prior studies examining the association between HDP and incident AFib^{4, 13-16} have 133 134 typically considered AFib as part of a composite outcome^{13, 15} or have focused solely on 135 preeclampsia.^{15, 17, 18} Further, most of these studies had relatively short (median) follow-136 up times (e.g., one,¹⁴ two,¹⁷ and seven¹⁹ years), did not consider death as a competing 137 risk, and failed to control for several important confounders. Further, despite evidence 138 that HDPs may represent distinct disease phenotypes.^{7, 20} which present with varying 139 levels of acute severity, no studies have examined potential dose-response associations 140 between distinct HDP subtypes [e.g., chronic hypertension in pregnancy, (de novo) 141 gestational hypertension] and incident AFib.

142

143 Given the rising social, economic, and public health burden of AFib,^{11, 21} and a growing 144 body of evidence suggesting that females are more likely to be symptomatic,²² report lower overall quality of life, experience greater functional impairment,²³ have a higher 145 146 susceptibility to AFib as their blood pressure increases,²⁴ and are diagnosed later in the 147 disease course compared to males,²⁵ more evidence is needed about the relationship between HDP and its subtypes as sex-specific risk factors for AFib.¹⁴ To address these 148 149 knowledge gaps, our primary aim was to examine the association between exposure to 150 any HDP in a first singleton pregnancy and subsequent incident AFib using a competing 151 risks analytic framework. Our secondary aim was to evaluate potential dose-response

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

relationships between the severity of HDP (based on specific HDP subtypes) and incidentAFib using the same analytical approach.

154

155 Methods

156 This study followed published methodological guidance on assessing CVD risk in people

157 with a history of HDP using administrative healthcare data.⁷ We also used the REporting

158 of studies Conducted using Observational Routinely-collected health Data (RECORD)

159 statement²⁶ to guide study reporting. A copy of our completed RECORD checklist is

160 provided in Table S1.

161

We acknowledge that both gender expression and biological sex exist on a spectrum and have striven to use gender neutral terminology as much as possible. When the terms women/woman and maternal are used this manuscript, they should be interpreted inclusively.

166

167 Data Availability Statement

The dataset used in this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email:das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

174	the computer programs may rely upon coding templates or macros that are unique to
175	ICES and are therefore either inaccessible or may require modification.

176

177 Study Design and Setting

This was a population-based retrospective cohort study of nulliparous women discharged from Ontario hospitals for obstetrical delivery of their first live or stillborn singleton infant between April 1, 2002 and December 31, 2017 (index date of cohort entry). Subjects were followed until they had an incident AFib diagnosis, a recorded death date, were no longer eligible for OHIP (i.e., migrated out of Ontario), or at the end of study follow-up (December 31st, 2019), whichever came first.

184

Ontario is Canada's most populous province and provides essential medical services, inhospital prescription drugs, and immunizations free of charge for all residents through the Ontario Health Insurance Program (OHIP). Data generated from the use of routine healthcare services are maintained at ICES. ICES is an independent, non-profit research institute whose legal status under Ontario's health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement.

192

193 Data Sources

We used data obtained from record-level, coded, population-based administrative databases that were linked using unique encoded identifiers and analyzed at ICES (Figure S1; details about each dataset are provided in Table S2). Briefly, demographic

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

197 information at index delivery (maternal date of birth, residential postal code) was obtained 198 from the Registered Persons Database (RPDB), a population registry file of all people 199 eligible for OHIP since 1991 and enables linkage with other data holdings at ICES. The 200 mother-baby database (MOMBABY), which uses the Canadian Institutes for Health 201 Information Discharge Abstract Database (CIHI-DAD) to link in-hospital maternal and 202 infant delivery records, was used to obtain information about maternal parity as well as 203 baby's sex, date of birth, birthweight, and gestational age at birth. Information about 204 diagnoses and procedures from clinical encounters and were obtained from the National 205 Ambulatory Care Reporting System (NACRS), OHIP, CIHI-DAD, and the Same Day 206 Surgery (SDS) database, as well as several ICES-derived cohorts (Ontario Hypertension 207 Dataset, Ontario Diabetes Dataset, Ontario Crohn's and Colitis Cohort, Ontario 208 Rheumatoid Arthritis Dataset).

209

We used the Ontario portion of the Immigration, Refugee and Citizenship Canada's (IRCC) permanent resident database to ascertain immigration status. Information about area-level socioeconomic status was ascertained using the Ontario Marginalization Index (ON-Marg; quintiles)²⁷ by linking residential postal codes (RPDB) with census data, and we used the Rural Index of Ontario (RIO) to determine subject rurality at index delivery. The postal code conversion file was used to convert subject postal codes to area-level quintiles.

- 217
- 218
- 219

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

220 Subject Eligibility

221 All adults aged ≥18 years who delivered their first live or stillborn infant at ≥20 weeks 222 gestational age, or >500-gram birthweight, between April 1, 2002 and December 31, 2017 223 (index date) were initially eligible for inclusion. Individuals were excluded if they were >55 224 years of age, not Ontario residents, had an invalid health card number, a recorded death 225 date prior to their index date, were not eligible for OHIP coverage, or had <2 years of 226 continuous coverage, prior to cohort entry. People with a history of/ongoing AFib at the 227 time of index delivery and those missing data required for ON-Marg (n= 8.587; 1.1%) 228 were also excluded. During the exposure accrual period, approximately 98% of all births 229 in Ontario occurred in-hospital.²⁸

230

231 Study Variables

232 A directed acyclic graph (DAG) illustrating the hypothesized relationships between study

variables (i.e., primary exposure, outcome, relevant confounders) is shown in Figure S2.

234

235 Primary and Secondary Exposures

The primary exposure was a composite 'any HDP' variable defined as any diagnosis of gestational hypertension, chronic hypertension in pregnancy, preeclampsia, chronic hypertension with superimposed preeclampsia (superimposed preeclampsia), eclampsia, or unspecified HDP in subjects' first obstetrical delivery. Secondary exposures included each individual HDP within the composite HDP exposure.

241

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

242	No case-finding definitions/algorithms for 'any HDP', or individual HDP subtypes, have	
243	been validated on Ontario population-based administrative data. As such, each HDP	
244	exposure was identified by applying the best available, and most relevant, case-finding	
245	definition validated in other jurisdictions to each subject's discharge abstract (Table S3). ^{7,}	
246	²⁹ We also searched for 'unspecified' HDP by looking for any International Classification	
247	of Disease, Tenth Revision (ICD-10) code beginning with O16 in each subject's obstetrical	
248	discharge abstract.	
249		
250	We employed a hierarchical 'severity coding' approach to exposure classification whereby	

any subject whose discharge abstract met the case-finding definition for >1 HDP subtype
had their exposure status re-coded such that only their most severe diagnosis was
recorded. Further details on the use of this approach are provided in Data Supplement
S4.

255

256 Outcome and Competing Risk

The primary outcome was incident AFib, which was identified using a case-finding definition previously validated in Ontario population-based administrative data (Table S4).³⁰ This algorithm has a reported specificity of 99%, and a positive predictive value of 71%, for the identification of incident AFib in Ontario adults \geq 20 years of age.³⁰ We did not differentiate between AFib type (i.e., paroxysmal, persistent, long-standing). The competing risk, all-cause death, was determined by the presence of a death date in the RPDB.

264

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

265 Confounders

266 We identified several risk factors for AFib that are also associated with, but not an effect 267 of, HDP (*i.e.*, confounders)³¹ based on input from clinical experts and evidence available from published literature.³²⁻³⁸ Behavioural and clinical factors identified as potential 268 269 confounders included: maternal age at delivery, pre-existing diabetes mellitus, polycystic 270 ovary syndrome, sleep apnea, smoking, kidney disease, chronic immune-mediated 271 inflammatory conditions, and pre-pregnancy obesity. We used ON-Marg material 272 resources dimension²⁷ guintiles to control for potential confounding by area-level socioeconomic status.^{39, 40} All confounders were treated as time-fixed and assessed only 273 274 at baseline. Further details about the methods used to identify these conditions are 275 summarized in Table S4.

276

277 Follow-up for Outcome and Competing Risk

Subjects were followed until they had an incident AFib diagnosis (outcome), a recorded death date in the RPDB (competing risk), were no longer eligible for OHIP, or at the end of study follow-up, whichever came first. All subjects who were eligible for OHIP, were still alive, and did not fulfil the algorithm for AFib by December 31st, 2019 were censored.

282

283 Statistical Methods

284 Descriptive Analyses

Baseline characteristics and comorbidities (i.e., conditions present at any time prior to index delivery) are presented as medians (quartile (Q)3 - Q1) and number affected (n), percentages (%) for categorical variables. We assessed differences in baseline

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

characteristics between HDP exposure status using absolute standardized differences (ASD). ASD >10% were considered indicative of potentially meaningful differences between the exposure and characteristic being assessed.⁴¹ We also calculated the proportion of subjects diagnosed with each HDP subtype over the study period. In accordance with ICES privacy policies, small cells (counts <6) have been suppressed or combined to reduce the risk of reidentification.

294

295 Crude and Multivariable Cause-Specific Cox Proportional Hazards Regression

Prior to fitting statistical models, each study variable was assessed for missingness, the presence of extreme/influential values, and possibly erroneous data (as appropriate). Phi coefficients were used to assess the strength of correlation between dichotomous variables; coefficients of ≥ 0.2 were interpreted as at least moderately correlated variables.⁴²

301

302 Cause-Specific Cox Proportional Hazards Regression

We used competing-risks Cox proportional hazards regression to compute crude and multivariable-adjusted cause-specific hazard ratios (csHRs), and accompanying 95% Cls, to assess the association between history of any HDP, and specific HDP subtypes and (a) incident AFib in those still alive during follow-up as well as (b) all-cause mortality in the absence of a prior AFib diagnosis.

308

309 We fit separate models for incident AFib and all-cause mortality, treating subjects who 310 died, or were diagnosed with AFib, as censored in each respective model. We also tested

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

for multiplicative interaction between HDP and material resources given known disparities
in the burden of HDP and AFib according to socioeconomic status.^{43, 44} Calendar time
was used as the underlying time scale in all models.

314

For each cause-specific model, we used both graphical and formal statistical tests (Schoenfeld residuals and residual plots,⁴⁵ Kolmogorov-type supremum tests⁴⁶) to assess whether the effect of each variable on the csHazard function was constant over time.⁴⁷ A 2-sided p-value <0.05 was considered evidence that the variable being tested likely violated the PH assumption. ^{46, 48}

320

321 After visually assessing residual plots, and considering the results of formal statistical 322 tests, the PH assumption was considered violated for gestational hypertension (AFib 323 model only), as well as the covariates age (both cause-specific models) and material 324 resources (mortality models only). As such, in AFib models for subjects exposed to 325 gestational hypertension, we performed a time-segmented analysis by restricting follow-326 up time to >4.5 years post-delivery, as the PH assumption held for this follow-up period. In models assessing all-cause mortality, we stratified by material resources.⁴⁹ Final 327 328 models included maternal age at delivery as a restricted cubic spline with five knots placed at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles.⁵⁰ 329

330

331 Sensitivity Analyses

332 We carried out three sensitivity analyses: two were carried out to assess how (1) 333 excluding subjects with certain pre-existing conditions (Table S5), and (2) restricting

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

follow-up times for observing AFib/mortality events, impacted effect estimates. A third
sensitivity analysis assessed the potential impact of unmeasured confounding on the
effect estimates generated (E-values). Further details are provided in Data Supplement
S6.
All analyses were carried out using SAS Enterprise Guide (Version 8.3, SAS Institute,

Cary, NC). Forest plots were generated using the ggplot2 package⁵¹ in RStudio (v. 2023.12.1.402) to visualize effect estimates (95% CIs) and facilitate comparisons between HDP exposures.

343

344 Ethics Approval

The use of the data in this project is authorized under section 45 of Ontario's Personal Health Information Protection Act (PHIPA) and does not require review by a Research Ethics Board.

348

349 Results

350 Selection of Study Subjects

We identified 2,105,409 women discharged from an Ontario hospital for a potentially eligible obstetrical delivery between April 1, 2002 and December 31, 2017. After excluding non-Ontario residents, people <18 and >55 years of age, individuals with a recorded death date prior to their index date , <2 years of continuous OHIP eligibility, and a history of/ongoing AFib prior to or at index delivery, in addition to non-nulliparous women and subsequent deliveries of otherwise eligible women, subjects with multiple gestation first

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

pregnancies, and people with missing ON-Marg information, a total of 771,521 subjects
were included in the study cohort (Figure 1).

359

360 Baseline Maternal Characteristics at Study Entry

Most maternal risk factors and adverse pregnancy outcomes were more prevalent in people with a history of HDP. However, only a moderate number of differences were considered potentially meaningful (ASD >10%); Table 1.

364

365 Individuals with a history of HDP in their first obstetrical delivery were older than those 366 with no HDP diagnosis (ASD for median age, 13%) and were more likely to have pre-367 existing diabetes and hypertension. In contrast, subjects with a history of HDP were less 368 likely to be an immigrant, to reside in an urban area, or in neighborhoods with the highest 369 quintile of racialized and newcomer populations (Table 1). The prevalence of pre-existing 370 cardiovascular and endocrine conditions at baseline was numerically equivalent to, or 371 marginally higher in, subjects diagnosed with HDP (Table S6). Additional details related 372 to baseline obstetrical characteristics are provided in Table S7.

373

374 Hypertensive Disorder of Pregnancy Exposure Status and Incident Chronic Hypertension
375 Post-delivery

Approximately 8% of study subjects were diagnosed with HDP during the 16-year exposure accrual period (79.7 per 1,000 deliveries, n=61,486). The most common diagnosis was gestational hypertension (52.4 per 1,000 deliveries, n=40,460); the least

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

379	common was eclampsia (1.1 per 1,000 deliveries, n=824). A total of 1,691 subjects had a
380	diagnostic code for unspecified HDP (2.2 per 1,000 deliveries) (Figure 2).

381

Nearly 5% (n= 36,507) of study subjects were diagnosed with incident chronic hypertension at some point after pregnancy during the follow-up period. It was especially prevalent in subjects diagnosed with gestational hypertension (n=6,486, 16%) and preeclampsia (n=2,030, 14%) in their index delivery.

386

387 Incidence Rates and Time to Event Analyses

388 The total person-time of follow-up was 7,380,304 person-years (median follow-up 9.5 389 years), during which there were 2,483 (0.3%) incident AFib diagnoses and 2,951 (0.4%) 390 deaths. The crude cause-specific incidence rate (95% CI) of AFib ranged from 4.52 (3.96-391 5.08) per 10,000 person-years for gestational hypertension to 10.18 (7.13-13.24) per 392 10,000 person-years for chronic hypertension in pregnancy. Crude mortality rates (95%) 393 CI) in those without a prior AFib diagnosis ranged from 4.59 (4.03-5.16) per 10,000 394 person-years for gestational hypertension to 11.97 (6.29-17.66) per 10,000 person-years 395 for superimposed preeclampsia; Table 2.

396

The median age (Q1-Q3) of subjects with AFib was 30 (26-34 years), with 32% aged 40 years or older at their time of diagnosis, and the median age of those who died was 29 years (23-33 years), with 33% aged 40 years of age or older at their time of death. A total of 766,087 subjects were censored [n=26,926 (3.5%) due to a lapse in OHIP coverage; n= 739,161 (95.8%) at end of study].

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

402 When HDP exposure status was considered collectively (i.e., exposure to any HDP 403 subtype), the median time to event was nearly identical for both AFib and all-cause 404 mortality [7.1 years (2,574 days)] vs. [2,567 days (7.0 years)], respectively). However, 405 when each HDP exposure was considered individually, there was considerable 406 heterogeneity with respect to median time-to-event for both event types (Figure 3). 407 Specifically, subjects diagnosed with preeclampsia had the shortest median time to an 408 incident AFib diagnosis at approximately 5.5 years, while those diagnosed with eclampsia 409 had the longest median time to an AFib diagnosis at approximately 11.8 years. Further, 410 the median time to an incident AFib diagnosis was most similar between subjects 411 diagnosed with unspecified HDP and chronic hypertension in pregnancy (6.1 and 6.4 412 years, respectively), while the median time to death was most similar between those 413 diagnosed with unspecified HDP and superimposed preeclampsia (8.7 and 8.3 years, 414 respectively).

415

416 Cause-Specific Cumulative Incidence Curves

417 Cause-specific cumulative incidence curves for incident AFib and all-cause mortality, 418 stratified by HDP exposure status, are shown in Figure 4. Subjects with a history of any 419 HDP in their first singleton delivery had a consistently higher incidence of AFib and all-420 cause mortality compared to their unexposed counterparts over the follow-up period; 421 differences in these curves were apparent within approximately two years of the 422 pregnancy. For all-cause mortality, clear differences in these curves occurred slightly later, 423 at approximately three years post-delivery (Figure 4). Similar findings were noted for each 424 HDP subtype (Figures S4, S5).

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

425 Cause-Specific Hazard of AFib and All-Cause Mortality

After adjusting for confounders, we found that a history of any HDP in a first obstetrical delivery was associated with a 45% increased csHazard of incident AFib (adjusted csHR 1.45, 95% CI: 1.28-1.64), as well as an increased csHazard of death in subjects without a prior AFib diagnosis (adjusted csHR 1.31, 95% CI: 1.16-1.47) (Figures 5A and 5B, respectively).

431

432 With respect to specific HDP subtypes, we found that a history of gestational 433 hypertension, preeclampsia, and chronic hypertension in pregnancy were all associated 434 with an increased csHazard of incident AFib [adjusted csHR (95% CI): 1.49 (1.25-1.78), 435 1.53 (1.20-1.96), and 2.24 (1.55-3.23), respectively]; Figure 5A. While crude estimates 436 indicated a significant cause-specific association between superimposed preeclampsia 437 and incident AFib, the observed relationship was attenuated and no longer significant after multivariable adjustment (csHR 1.70, 95% CI: 0.84 to 3.43); Table S8. We also found 438 439 that a history of preeclampsia, unspecified HDP, chronic hypertension in pregnancy, and 440 superimposed preeclampsia were each independently associated with an increased 441 csHazard of death in subjects without an AFib diagnosis [adjusted csHR (95% CI): 1.43 442 (1.13-1.81), 1.91 (1.13-3.23), 2.04 (1.43-2.91), and 2.12 (1.20-3.78), respectively]; Figure 443 5B. Crude estimates also indicated a significant cause-specific association between both 444 gestational hypertension and eclampsia and all-cause mortality. However, these 445 relationships were attenuated and no longer significant after multivariable adjustment 446 [csHR (95% CI): 1.13 (0.97-1.31) and 1.91 (0.96-3.83), respectively]; Table S9.

447

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

448 Dose-Response Relationships

449 As summarized in Table 3, we identified associations suggestive of 'dose-response' 450 relationship whereby both the severity of *de novo* HDP diagnoses, and exposure to pre-451 pregnancy chronic hypertension, were associated with higher cause-specific rates of AFib 452 and all-cause mortality. Specifically, a history of gestational hypertension in a first delivery 453 showed the smallest significant cause-specific association with incident AFib [adjusted 454 csHR (95% CI) 1.49 (1.25-1.78)] compared to more severe de novo HDP exposures, such as preeclampsia. However, a history of chronic hypertension in pregnancy was most 455 456 strongly associated with incident AFib compared to all other HDP diagnoses, with an 457 adjusted csHR (95% CI) of 2.24 (1.55-3.23). We also noted that chronic hypertension in 458 pregnancy was more strongly associated with all-cause mortality without a prior AFib 459 diagnosis compared to preeclampsia [csHR (95%CI) 2.04 (1.43-2.91) vs. 1.43 (1.13-460 1.81), a *de novo* diagnosis. Further, a history of exposure to both pre-pregnancy 461 hypertension and preeclampsia (i.e., superimposed preeclampsia) in a first pregnancy 462 showed the strongest cause-specific association with mortality compared to all other HDP 463 subtypes (csHR 2.12, 95%CI: 1.20-3.78).

464

465 Sensitivity Analyses

When the observation period for incident AFib events and all-cause mortality was limited to >90 days post index delivery, the csHazard of AFib in subjects who were still alive during follow-up was attenuated slightly in those exposed to any HDP, chronic hypertension in pregnancy, and preeclampsia in their first obstetrical delivery. However, all estimates remained statistically significant. Similar results were found for estimates of

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

death without a prior AFib diagnosis (Table S10). Estimates obtained for models limited
to >120 days of follow-up were similar to those limited to >90 days of follow up (not
reported).

474

475 When models were re-run after excluding subjects with baseline cardiovascular and 476 endocrine conditions, most estimates remained essentially unchanged or were minimally 477 attenuated (Table S10). The only exception was the estimate for subjects exposed to 478 chronic hypertension in pregnancy, where the csHR for AFib increased slightly from 2.24 479 (95% CI: 1.55-3.23) to 2.42 (95% CI: 1.63-3.59) after excluding subjects with these 480 baseline conditions. Similar results were found for all-cause mortality without a prior AFib 481 diagnosis after subjects with these pre-existing conditions were excluded from the 482 analysis [adjusted csHR (95% CI): 2.05 (1.43-2.92) vs. 2.20 (1.51-3.19)].

483

484 E-values indicated that effect estimates were generally robust to unmeasured 485 confounding (Table S11). Specifically, for gestational hypertension, chronic hypertension 486 in pregnancy, and preeclampsia, an unmeasured confounder would need to at least 487 double the risk of AFib and be at least twice as prevalent in those with a history of these 488 HDPs, to explain away the observed associations. Similarly, for chronic hypertension in 489 pregnancy, preeclampsia, superimposed preeclampsia, and unspecified HDP, an 490 unmeasured confounder would need to at least double the risk of mortality before a prior 491 AFib diagnosis and be at least twice as prevalent in those with a history of these 492 exposures, to explain away the observed associations.

493

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

494 Discussion

495 This population-based retrospective cohort study of 771,521 nulliparous women has three 496 novel findings. First, a history of 'any' HDP is independently associated with an increased 497 csHazard of both AFib and all-cause mortality, and these associations were observed in 498 relatively young women (median time-to-event: 7 years postpartum). Second, a history of 499 gestational hypertension, preeclampsia, and chronic hypertension in pregnancy are each 500 independently associated with an increased csHazard of incident AFib, whereas a history 501 of preeclampsia, unspecified HDP, chronic hypertension in pregnancy, and superimposed 502 preeclampsia are each independently associated with an increased csHazard of all-cause 503 mortality without a prior AFib diagnosis. Third, a dose-response relationship may exist 504 within these associations, as both HDP severity, as well as the presence of pre-pregnancy 505 chronic hypertension, were found to be associated with higher rates of both adverse 506 outcomes.

507

508 The pathophysiologic mechanism(s) underlying the observed associations are complex and multifactorial.⁷ However, HDP and AFib share a number of important features,⁵² such 509 as cardiac remodelling,⁵³ endothelial dysfunction,^{54, 55} and inflammation,^{56, 57} which are 510 511 likely central to the development of AFib in individuals with a history of HDP. This is further 512 supported by evidence indicating that HDP-associated inflammation and endothelial 513 dysfunction can persist well into the postpartum period,^{52, 54, 56} or become permanent,^{58,} 514 ⁵⁹ resulting in extensive changes to endothelial cell function in both small and large vessels.^{60, 61} Indeed, recent work⁸ also suggests that cardiovascular alterations 515 516 associated with HDP lead to early vascular ageing, which could explain the increased

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

517 predisposition to AFib noted in individuals exposed to HDP in this study– especially given
518 that AFib is typically associated with older age.

519

520 Only a limited number of cohort studies have reported significant associations between a 521 history of HDP and incident AFib.4, 14, 16 With respect to any HDP, we found a 522 comparatively lower rate of incident AFib than that reported by Leon et al.,¹⁶ who reported 523 a nearly 2-fold higher adjusted hazard of AFib in people exposed to HDP after 9.3 median 524 years of follow-up. In comparison, after 9.5 median years of follow-up, we found a 1.4-525 fold higher adjusted csHazard of AFib, and a 1.3-fold higher adjusted csHazard of all-526 cause mortality in those with a history of any HDP. A few factors could explain these 527 findings.

528

First, although Leon et al.¹⁶ controlled for some important confounders, such as maternal 529 530 age and diabetes, several others (e.g., pre-pregnancy body mass index (BMI), tobacco 531 use, kidney disease) were not accounted for. Second, their data were analyzed using 532 conventional Cox models, which are carried out under the assumption of noninformative censoring.⁶² However, in the presence of ≥ 1 competing risk,⁶³ this assumption is violated, 533 534 and can result in upward-biased effect estimates.^{62, 64} In this study, we accounted for a 535 more robust set of confounders and used cause-specific Cox models to appropriately 536 address competing risks, which may explain our comparatively lower adjusted HRs for 537 both incident AFib and all-cause mortality.

538

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

Robust evidence suggests an association between history of HDP and risk of both CVD and mortality within the first decade following an affected pregnancy.^{65, 66} A recently published study⁶⁵ reported a 1.2-fold increased risk of all-cause death in women <50 years of age with a history of any HDP compared to their unexposed counterparts. Despite this, only one published study¹⁴ reporting estimates of AFib risk in people exposed to HDP acknowledged the omission of mortality assessment as a study limitation.

546

In alignment with previous work,⁶⁵ we found that a history of any HDP in a first obstetrical 547 548 delivery was associated with a 30% increased rate of death without a prior AFib diagnosis 549 after 9.5 years of follow-up. Importantly, the median age of subjects who died during the 550 follow-up period was 29 years, with 67% of subjects being younger than 40 years of age 551 when they died. Further, although both incident AFib and death were rare outcomes, 552 death was slightly more common than AFib (2,951 vs. 2,483 respectively). These findings 553 underscore the importance of considering mortality as a competing risk for non-fatal CVD 554 outcomes in this relatively young population, as failure to do so could result in artificially 555 inflated estimates of association.

556

557 We identified associations suggestive of dose-response relationships whereby both HDP 558 severity and the presence of pre-pregnancy chronic hypertension were associated with 559 higher cause-specific rates of both AFib and all-cause mortality. While the increasing 560 magnitude of these point estimates suggests a dose-response pattern, cautious 561 interpretation is needed due to overlapping 95% confidence intervals and non-significant

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

562 estimates for specific diagnoses, likely due at least in part to insufficient power to examine 563 specific associations among subtypes. Further, these associations did not directly align 564 with our 'hierarchical' definition of HDP severity, which was assessed from the viewpoint 565 of their acute clinical consequences for mother and fetus.⁷ Specifically, during exposure 566 classification, we considered chronic hypertension in pregnancy to be the second most 567 severe HDP diagnosis. However, it was associated with the highest csHazard of AFib and 568 second highest csHazard of mortality without a prior AFib diagnosis [adjusted csHR (95% 569 CI) 2.24 (1.55-3.23) and 2.04 (1.43-2.91), respectively]. Indeed, if future studies 570 assessing CVD risk in people with a history of HDP continue to examine HDP as a 571 composite exposure or adopt a narrow definition of HDP severity, critical dose-response 572 associations may remain unidentified.⁷

573

574 Despite the obvious time-varying nature of HDP and CVD risk factors, most prior work 575 assessing CVD risk in people with a history of HDP has employed a first pregnancy, time-576 fixed, approach to exposure ascertainment and data analysis.⁶⁷ In this study, we also 577 defined HDP exposure status according to subjects' first delivery, and only adjusted for 578 confounders that were assessed prior to cohort entry. Consequently, we were unable to 579 account for changes in HDP exposure and confounder status over time and did not assess the cumulative effect of exposure to HDP in subsequent pregnancies on incident 580 581 AFib. As such, our effect estimates may be subject to further residual confounding and/or 582 other time-related bias.⁶⁸ However, a few published studies, described as follows, can 583 provide important insight about the robustness of this approach within our context.

584

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

585 One recent study¹⁵ reported that the adjusted hazard of arrhythmia for people with a 586 history of preeclampsia in a first pregnancy was consistent with findings from a sensitivity 587 analysis wherein preeclampsia was treated a time-dependent variable [adjusted HR (95% 588 CI): 1.37 (1.23 to 1.54) vs. 1.29 (1.14 to 1.45), respectively]. Additional studies^{68, 69} have 589 also found minimal differences between estimates of CVD risk generated using marginal 590 structural (time-varying) Cox models compared to those generated using time-fixed 591 analyses. As such, while the robustness of our findings should be assessed in models 592 that account for the time-varying nature of HDP and confounders, prior research suggests 593 that CVD risk may be primarily driven by HDP exposure in a first pregnancy and time-594 varying confounding may have a minimal impact on effect estimates.⁶⁸

595

596 Strengths and Limitations

597 Our large sample size and use of population-based data sources from the most populous 598 ethnically and culturally diverse province in Canada enhances the generalizability of our 599 findings. We followed established guidance on the reporting of studies carried out using 600 routinely collected data,²⁶ controlled for several important confounders, accounted for the 601 competing risk of death, and our findings were robust to several sensitivity analyses.

602

Although we controlled for a robust set of confounders, we cannot rule out the possibility that residual confounding may have impacted our results. Pre-pregnancy BMI was unavailable for nearly 70% of subjects, thus, we adjusted for clinically documented obesity by identifying ICD-10 codes for this diagnosis in outpatient or inpatient records. However, individuals with codes for this condition likely only represent extreme cases, so

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

control for this factor was likely incomplete, and may have resulted in spuriously inflated
associations. Despite this, the results of our E-value sensitivity analysis provide some
reassurance about the robustness of our findings to unmeasured confounding.

611

612 We considered incident chronic hypertension as an intermediate factor in the causal 613 pathway between HDP and incident AFib and, thus, did not include it in multivariable 614 models to prevent overadjustment bias.⁷⁰ However, given the strong association between 615 history of chronic hypertension in pregnancy and incident AFib identified in this study, the 616 shared pathological features of chronic hypertension and AFib (e.g., left ventricular 617 hypertrophy, diastolic dysfunction),⁵³ and that incident chronic hypertension post-HDP 618 was especially prevalent in subjects diagnosed with gestational hypertension (16%) and 619 preeclampsia (14%), a formal causal mediation analysis^{71, 72} should be conducted to 620 further elucidate the role that post-pregnancy chronic hypertension might play in this 621 association.

622

623 Conclusions

A history of gestational hypertension, preeclampsia, and chronic hypertension in pregnancy are each independently associated with a higher csHazard of incident AFib, with associations observed in relatively young women. Given its rapidly increasing global prevalence and significant morbidity and mortality burden, AFib has become one of the most substantial CVD challenges of the 21st century– particularly for women. These findings underscore the critical importance of (a) incorporating information about history of HDP in risk calculation/stratification for both arrhythmic *and* non- arrhythmic forms of

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 631 CVD, (b) improved population-based surveillance of traditional and female-specific CVD
 632 risk factors, and (c) the development of targeted prevention strategies designed to reduce
 633 the occurrence, and overall burden, of HDP.
- 634

635 Acknowledgements

636 Parts of this material are based on data and/or information compiled and provided by 637 CIHI, the Ontario Ministry of Health (MOH), and Immigration, Refugees and Citizenship 638 Canada (IRCC) current to September 2020. The analyses, conclusions, opinions and 639 statements expressed herein are solely those of the authors and do not reflect those of 640 the funding or data sources; no endorsement is intended or should be inferred. This 641 document used data adapted from the Statistics Canada Postal Code^{OM} Conversion File, 642 which is based on data licensed from Canada Post Corporation, and/or data adapted from 643 the Ontario Ministry of Health Postal Code Conversion File, which contains data copied 644 under license from ©Canada Post Corporation and Statistics Canada. Adapted from 645 Statistics Canada, this study used census 2001, 2006, and 2016. This does not constitute 646 an endorsement by Statistics Canada of this product. We thank the Toronto Community 647 Health Profiles Partnership for providing access to the Ontario Marginalization Index.

648

649 Sources of Funding

This study was supported by ICES, which is funded by an annual grant from the Ontario
MOH and the Ministry of Long-Term Care. Additional funding was provided by a Canadian
Cardiovascular Society Early Career Arrhythmia and Atrial Fibrillation (ECA3) Grant.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

654 Disclosures

When this project was initiated, DBF was employed by the University of Ottawa and had an academic appointment at the Children's Hospital of Eastern Ontario Research Institute; although she continues to hold adjunct appointments in both institutions, she is now employed by Pfizer and works on an unrelated topic. No other authors have any conflicts of interest to disclose.

660

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

662 References

- 1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive
- 664 Disorders of Pregnancy Working G. Diagnosis, evaluation, and management of the
- 665 hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can.
- 666 2014;36(5):416-41.
- 667 2. James PR, Nelson-Piercy C. Management of hypertension before, during, and
 668 after pregnancy. Heart. 2004;90(12):1499.

669 3. Anthony J, Damasceno A, Ojjii D. Hypertensive disorders of pregnancy: what the

670 physician needs to know. Cardiovasc J Afr. 2016;27(2):104-10.

4. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O,

672 et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy.

573 Journal of the American College of Cardiology. 2020;75(18):2323-34.

5. Coutinho T, Lamai O, Nerenberg K. Hypertensive Disorders of Pregnancy and

675 Cardiovascular Diseases: Current Knowledge and Future Directions. Curr Treat Options

676 Cardiovasc Med. 2018;20(7):56.

677 6. Wu R, Wang T, Gu R, Xing D, Ye C, Chen Y, et al. Hypertensive Disorders of

678 Pregnancy and Risk of Cardiovascular Disease-Related Morbidity and Mortality: A

679 Systematic Review and Meta-Analysis. Cardiology. 2020;145(10):633-47.

680 7. Johnston A, Smith GN, Tanuseputro P, Coutinho T, Edwards JD. Assessing

681 cardiovascular disease risk in women with a history of hypertensive disorders of

682 pregnancy: A guidance paper for studies using administrative data. Paediatr Perinat

683 Epidemiol. 2024.

Johnston et al. 2024

705

16.

Original Research Article Submission: Go Red Special Edition

684	8.	Werlang A, Paquin A, Coutinho T. The EVA Study: Early Vascular Aging in		
685	Women With History of Preeclampsia. J Am Heart Assoc. 2023;12(8):e028116.			
686	9.	Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al.		
687	Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-			
688	Analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2).			
689	10.	Al Bahhawi T, Aqeeli A, L Harrison S, A Lane D, Buchan I, Skjoth F, et al.		
690	Pregnancy-related complications and incidence of atrial fibrillation: a systematic review			
691	and meta-analysis. EP Europace. 2021;23(Supplement_3).			
692	11.	Li H, Song X, Liang Y, Bai X, Liu-Huo W-S, Tang C, et al. Global, regional, and		
693	national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a			
694	global burden of disease study, 2019. BMC Public Health. 2022;22(1):2015.			
695	12.	Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation:		
696	An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-21.			
697	13.	Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias		
698	after maternal placental syndromes: HAD MPS Study. Heart. 2012;98(15):1136-41.			
699	14.	Park Y, Cho G, Roh S, Na J, Oh M. Increased Cardiac Arrhythmia After		
700	Pregnancy-Induced Hypertension: A South Korean Nationwide Database Study. J Am			
701	Heart Assoc. 2022;11(2):e023013.			
702	15.	Havers-Borgersen E, Stahl A, Johansen M, Jøns C, Køber L, Fosbøl EL. Pre-		
703	eclampsia and long-term risk of arrhythmias. European Journal of Preventive			
704	Cardiology. 2024:zwae176.			

JP, et al. Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of

Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

707 Linked Electronic Health Records: A CALIBER Study. Circulation. 2019;140(13):1050-708 60.

709 17. Oliver-Williams C, Stevens D, Payne RA, Wilkinson IB, Smith GCS, Wood A.

710 Association between hypertensive disorders of pregnancy and later risk of

711 cardiovascular outcomes. BMC Medicine. 2022;20(1):19.

712 18. Auger N, Potter BJ, He S, Healy-Profitos J, Schnitzer ME, Paradis G. Maternal

713 Cardiovascular Disease 3 Decades After Preterm Birth: Longitudinal Cohort Study of

714 Pregnancy Vascular Disorders. Hypertension (Dallas, Tex : 1979). 2020;75(3):788-95.

715 19. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-

716 Term Cardiovascular Risk in Women With Hypertension During Pregnancy. Journal of

the American College of Cardiology. 2019;74(22):2743-54.

718 20. Stuart JJ, Tanz LJ, Rimm EB, Spiegelman D, Missmer SA, Mukamal KJ, et al.

719 Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With

Hypertensive Disorders of Pregnancy. J Am Coll Cardiol. 2022;79(19):1901-13.

721 21. Deshpande S, Catanzaro J, Wann S. Atrial Fibrillation: Prevalence and Scope of

the Problem. Card Electrophysiol Clin. 2014;6(1):1-4.

723 22. Tan JL, Johnson L, Dziubinski M, Napiorkowski N, Witkowska O, Slusarczyk ME,

et al. Sex differences in presentation of atrial fibrillation: Findings from 30-day

ambulatory monitoring in real-world practice. American Heart Journal Plus: Cardiology

726 Research and Practice. 2022;22:100208.

727 23. Volgman AS, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, Naccarelli GV, et al.

728 Women and atrial fibrillation. Journal of Cardiovascular Electrophysiology.

729 2021;32(10):2793-807.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 730 24. Kanazawa S, Kaneko H, Yano Y, Suzuki Y, Okada A, Matsuoka S, et al. Sex
- 731 Differences in the Association Between Hypertension and Incident Atrial Fibrillation. J
- 732 Am Heart Assoc. 2023;12(5):e026240.
- 733 25. Ehdaie A, Cingolani E, Shehata M, Wang X, Curtis AB, Chugh SS. Sex
- 734 Differences in Cardiac Arrhythmias. Circulation: Arrhythmia and Electrophysiology.
- 735 2018;11(3):e005680.
- 736 26. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The

737 REporting of studies Conducted using Observational Routinely-collected health Data

- 738 (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
- 739 27. Matheson F, van Ingen T, Moloney G. 2021 Ontario marginalization index: user
- guide. Toronto, ON: St. Michael's Hospital (Unity Health Toronto) and Public Health
- 741 Ontario; 2023.
- 742 28. Table 13-10-0429-01 Live births and fetal deaths (stillbirths), by place of birth
- 743 (hospital or non-hospital) Ottawa, ON: Statistics Canada; 2023 [Available from:
- 744 <u>https://doi.org/10.25318/1310042901-eng.</u>
- 745 29. Johnston A, Dancey SR, Tseung V, Skidmore B, Tanuseputro P, Smith GN, et al.
- 746 Systematic review of validated case definitions to identify hypertensive disorders of
- pregnancy in administrative healthcare databases. Open Heart. 2023;10(2):e002151.
- 748 30. Tu K, Nieuwlaat R, Cheng SY, Wing L, Ivers N, Atzema CL, et al. Identifying
- 749 Patients With Atrial Fibrillation in Administrative Data. Can J Cardiol. 2016;32(12):1561-

750 5.

31. Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is and how todeal with it. Kidney Int. 2008;73(3):256-60.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 753 32. Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Polycystic ovary syndrome
- as a novel risk factor for atrial fibrillation: results from a national Danish registry cohort
- 755 study. Eur J Prev Cardiol. 2020:2047487320922927.
- 756 33. Zahid S, Khan MZ, Gowda S, Faza NN, Honigberg MC, Vaught A, et al. Trends,
- 757 Predictors, and Outcomes of Cardiovascular Complications Associated With Polycystic
- 758 Ovary Syndrome During Delivery Hospitalizations: A National Inpatient Sample Analysis
- 759 (2002–2019). J Am Heart Assoc. 2022;11(16):e025839.
- 760 34. Jaimchariyatam N, Na-Rungsri K, Tungsanga S, Lertmaharit S, Lohsoonthorn V,
- 761 Totienchai S. Obstructive sleep apnea as a risk factor for preeclampsia-eclampsia.
- 762 Sleep Breath. 2019;23(2):687-93.
- 763 35. Palma-Reis I, Vais A, Nelson-Piercy C, Banerjee A. Renal disease and
- hypertension in pregnancy. Clin Med (Lond). 2013;13(1):57-62.
- 765 36. Choi YJ, Choi EK, Han KD, Park J, Moon I, Lee E, et al. Increased risk of atrial
- fibrillation in patients with inflammatory bowel disease: A nationwide population-based
- 767 study. World J Gastroenterol. 2019;25(22):2788-98.
- 768 37. Jiang L, Tang K, Magee LA, von Dadelszen P, Ekeroma A, Li X, et al. A global
- view of hypertensive disorders and diabetes mellitus during pregnancy. Nat Rev
- 770 Endocrinol. 2022;18(12):760-75.
- 771 38. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et
- al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific
- 773 Statement From the American Heart Association. Circulation. 2020;141(16):e750-e72.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

39. Asare AO, Maurer D, Wong AMF, Ungar WJ, Saunders N. Socioeconomic Status

and Vision Care Services in Ontario, Canada: A Population-Based Cohort Study. The

776 Journal of Pediatrics. 2022;241:212-20.e2.

40. Inman M, Daneman D, Curtis J, Sochett E, Clarke A, Dunger DB, et al. Social

778 Determinants of Health Are Associated with Modifiable Risk Factors for Cardiovascular

779 Disease and Vascular Function in Pediatric Type 1 Diabetes. The Journal of Pediatrics.

780 2016;177:167-72.

41. Austin PC. Balance diagnostics for comparing the distribution of baseline

covariates between treatment groups in propensity-score matched samples. Stat Med.

783 2009;28(25):3083-107.

42. Austin PC. Using the Standardized Difference to Compare the Prevalence of a

785 Binary Variable Between Two Groups in Observational Research. Communications in

786 Statistics - Simulation and Computation. 2009;38(6):1228-34.

43. Kim MK, Lee SM, Bae S-H, Kim HJ, Lim NG, Yoon S-J, et al. Socioeconomic

status can affect pregnancy outcomes and complications, even with a universal

healthcare system. International Journal for Equity in Health. 2018;17(1):2.

790 44. Elin Danielsen L, Albert Marni J, Søren L-C, Kirsten F, Søren Paaske J, Mogens

T91 Lytken L, et al. Socioeconomic position and risk of atrial fibrillation: a nationwide Danish

cohort study. Journal of Epidemiology and Community Health. 2020;74(1):7.

793 45. The PHREG Procedure. 2017. In: SAS/STAT® 143 User's Guide [Internet]. Cary,

794 NC, USA: SAS Institute Inc.

795 46. Goldstein L, Ottesen R. Survival 101 - Just Learning to Survive. PharmaSUG
796 2017; May 14-17; Baltimore, MD2017.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 47. Austin PC, Fang J, Lee DS. Using fractional polynomials and restricted cubic
- splines to model non-proportional hazards or time-varying covariate effects in the Cox
- regression model. Stat Med. 2022;41(3):612-24.
- 800 48. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of
- 801 martingale-based residuals. Biometrika. 1993;80(3):557-72.
- 49. Hosmer D, Lemeshow S, May S. Applied Survival Analysis : Regression Modeling
- of Time-to-Event Data. 2nd ed. New Jersey: John Wiley & Sons, Inc.; 2008.
- 804 50. Harrell FE, Jr. Regression Modeling Strategies With Applications to Linear
- 805 Models, Logistic and Ordinal Regression, and Survival Analysis: Cham: Springer
- 806 InternationalPublishing; 2015.
- 807 51. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer808 Verlag; 2016.
- 809 52. Al Bahhawi T, Aqeeli A, Harrison SL, Lane DA, Skjøth F, Buchan I, et al.
- 810 Pregnancy-Related Complications and Incidence of Atrial Fibrillation: A Systematic
- 811 Review. J Clin Med. 2023;12(4):1316.
- 812 53. Bizhanov KA, Abzaliyev KB, Baimbetov AK, Sarsenbayeva AB, Lyan E. Atrial
- 813 fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).
- 814 J Cardiovasc Electrophysiol. 2023;34(1):153-65.
- 815 54. Östlund E, Al-Nashi M, Hamad RR, Larsson A, Eriksson M, Bremme K, et al.
- 816 Normalized endothelial function but sustained cardiovascular risk profile 11 years
- following a pregnancy complicated by preeclampsia. Hypertens Res. 2013;36(12):1081-

818 7.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

819	55.	Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac Remodeling: Endothelial
820	Cells	s Have More to Sav Than Just NO. Front Physiol. 2018:9:382.

- 56. van Rijn BB, Bruinse HW, Veerbeek JH, Post Uiterweer ED, Koenen SV, van der
- 822 Bom JG, et al. Postpartum Circulating Markers of Inflammation and the Systemic Acute-
- 823 Phase Response After Early-Onset Preeclampsia. Hypertension. 2016;67(2):404-14.
- 824 57. Korantzopoulos P, Letsas KP, Tse G, Fragakis N, Goudis CA, Liu T. Inflammation
- and atrial fibrillation: A comprehensive review. J Arrhythm. 2018;34(4):394-401.
- 826 58. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular
- 827 dysfunction in women with a history of preeclampsia and intrauterine growth restriction:
- 828 insights into future vascular risk. Circulation. 2010;122(18):1846-53.
- 829 59. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Valcamonico A, Metra M, et al.
- 830 Endothelial dysfunction and vascular stiffness in women with previous pregnancy
- 831 complicated by early or late pre-eclampsia. Ultrasound Obstet Gynecol. 2017;49(1):116-
- 832 23.
- 833 60. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, et al. Preeclampsia
- and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin
- 835 Resistance. The Journal of Clinical Endocrinology & Metabolism. 2004;89(12):6239-43.
- 836 61. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in
- 837 pregnancy and later cardiovascular risk: common antecedents? Circulation.
- 838 2010;122(6):579-84.
- 839 62. Schuster NA, Hoogendijk EO, Kok AAL, Twisk JWR, Heymans MW. Ignoring
- 840 competing events in the analysis of survival data may lead to biased results: a

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 841 nonmathematical illustration of competing risk analysis. Journal of Clinical
- 842 Epidemiology. 2020;122:42-8.
- 843 63. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the
- Presence of Competing Risks. Circulation. 2016;133(6):601-9.
- 845 64. Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, et al. Importance of
- 846 Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a
- 847 Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation. Circulation
- 848 Cardiovascular quality and outcomes. 2018;11(7):e004580-e.
- 849 65. Welters SM, de Boer M, Teunissen PW, Hermes W, Ravelli ACJ, Mol BW, et al.
- 850 Cardiovascular mortality in women in their forties after hypertensive disorders of
- 851 pregnancy in the Netherlands: a national cohort study. The Lancet Healthy Longevity.
- 852 2023;4(1):e34-e42.
- 853 66. Langlois AWR, Park AL, Lentz EJM, Ray JG. Preeclampsia Brings the Risk of
- 854 Premature Cardiovascular Disease in Women Closer to That of Men. The Canadian
- 855 journal of cardiology. 2020;36(1):60-8.
- 856 67. DeRoo LA. Hypertensive Disorders in Pregnancy and Future
- 857 Maternal Cardiovascular Disease: The Challenges of Looking Beyond First Pregnancy.
- 858 Paediatr Perinat Epidemiol. 2017;31(5):422-3.
- 859 68. Grandi SM, Vallée-Pouliot K, Reynier P, Eberg M, Platt RW, Arel R, et al.
- 860 Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular
- B61 Disease. Paediatr Perinat Epidemiol. 2017;31(5):412-21.

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition

- 862 69. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of
- 863 hypertensive disorders in pregnancy and the risk of incident hypertension and
- 864 cardiovascular disease. Int J Cardiol. 2018;270:273-5.
- 865 70. van Zwieten A, Tennant PWG, Kelly-Irving M, Blyth FM, Teixeira-Pinto A,
- 866 Khalatbari-Soltani S. Avoiding overadjustment bias in social epidemiology through
- 867 appropriate covariate selection: a primer. Journal of Clinical Epidemiology.
- 868 2022;149:127-36.
- 869 71. VanderWeele TJ. Causal mediation analysis with survival data. Epidemiology
- 870 (Cambridge, Mass). 2011;22(4):582-5.
- 871 72. Tyler V. Explanation in Causal Inference : Methods for Mediation and Interaction.
- 872 New York: Oxford University Press; 2015.
- 873 73. Nakazawa M. Functions for Medical Statistics Book with some Demographic
- 874 Data. 0.7.6 ed2024.
- 875

Tables

877 Table 1. Baseline maternal characteristics at study entry.

	Total	No HDP	HDP	ASD (%)
Fotal No. Study Subjects (%)	771,521 (100)	710,035 (92.0)	61,486 (8.0)	
Maternal Characteristics				
Age at First Delivery, Years				
Median (Q1-Q3)	29 (25-32)	29 (25-32)	29 (26-33)	13
Age Group (Years)				
<20	34,697 (4.5)	32,613 (4.6)	2,084 (3.4)	5
20 to 24	132,764 (17.2)	123,448 (17.4)	9,316 (15.2)	2
25 to 29	250,841 (32.5)	231,439 (32.6)	19,402 (31.6)	6
30 to 34	244,567 (31.7)	225,397 (31.7)	19,170 (31.2)	6
35 to 39	90,178 (11.7)	81,204 (11.4)	8,974 (14.6)	2
40 to 44	17,258 (2.2)	14,976 (2.1)	2,282 (3.7)	1
45 to 49	1,117 (0.1)	889 (0.1)	228 (0.4)	9
50+	99 (0.01)	69 (0.01)	30 (0.05)	10
Comorbid Conditions [≠]				
Diabetes Mellitus	11,296 (1.5)	8,828 (1.2)	2,468 (4.0)	17
Polycystic Ovary Syndrome	26,192 (3.4)	23,229 (3.3)	2,963 (4.8)	8
Sleep Apnea**	15,148 (2.0)	13,102 (1.8)	2,046 (3.3)	9
Ever Smoker	23,730 (3.1)	21,676 (3.1)	2,054 (3.3)	2
Kidney Disease	18,337 (2.4)	16,060 (2.3)	2,277 (3.7)	9
Chronic Immune-Mediated Inflammatory Conditions [†]	16,569 (2.1)	14,942 (2.1)	1,627 (2.6)	4
Obesity	2,359 (0.3)	1,788 (0.3)	571 (0.9%)	9
Baseline Hypertension	16,715 (2.2)	9,737 (1.4)	6,978 (11.3%)	42
Sociodemographic Characterist	ics			
Immigrant ^{††}	159,375 (20.7)	149,546 (21.1%)	9,829 (16.0%)	13
Rurality Index of Ontario (RIO20	08) [*]			
Urban	579,948 (75.2)	536,410 (75.5)	43,538 (70.8)	11
Suburban	140,165 (18.2)	126,912 (17.9)	13,253 (21.6)	9
Rural	47,714 (6.2)	43,371 (6.1)	4,343 (7.1)	4
Missing	3,694 (0.5)	3,342 (0.5)	352 (0.6)	1

ON-Marg Dimension				
Age and Labour Force Dimension	n			
Quintile 1	250,642 (32.5)	231,223 (32.6)	19,419 (31.6)	2
Quintile 5	103,732 (13.4)	94,977 (13.4)	8,755 (14.2)	3
Material Resources Dimension				
Quintile 1	166,892 (21.6)	153,917 (21.7)	12,975 (21.1)	1
Quintile 5	158,854 (20.6)	145,886 (20.5)	12,968 (21.1)	1
Households and Dwellings Dime	ension	• •		
Quintile 1	149,548 (19.4)	138,366 (19.5)	11,182 (18.2)	3
Quintile 5	184,498 (23.9)	170,461 (24.0)	14,037 (22.8)	3
Racialized and Newcomer Popul	ations Dimension			
Quintile 1	106,365 (13.8)	96,557 (13.6)	9,808 (16.0)	7
Quintile 5	234,329 (30.4)	218,336 (30.8)	15,993 (26.0)	11
Visible Minority Quintile	· _ ·		· · · · ·	
Quintile 1	161,174 (20.9)	146,182 (20.6)	14,992 (24.4)	9
Quintile 5	125,948 (16.3)	117,881 (16.6)	8,067 (13.1)	10
Missing	3,960 (0.5)	3,684 (0.5)	276 (0.4)	1

Note: Values are n (%) unless otherwise noted. An ASD >10% (**bold**) was interpreted as a potentially meaningful difference in a baseline characteristic between groups.

ASD= absolute standardized difference, SD= standard deviation, ON-Marg = Ontario Marginalization Index, OHIP = Ontario Health
 Insurance Program, IRCC = Immigration, Refugee, and Citizenship Canada, Q= quartile

the following conditions prior to cohort entry: lupus, inflammatory
 bowel disease, psoriatic arthritis, ankylosing spondylitis, and/or rheumatoid arthritis.

*RIO2008 categorized as Urban = RIO < 10, Suburban = RIO 10–39, Rural = RIO \geq 40

885 **Proxy variable based on having \geq 1 OHIP code for sleep study.

886 *^{††}* Has an IRCC landing date

Table 2. Total number of events, person-years of follow-up, cause-specific incidence rates, and incidence rate ratios for incident atrial fibrillation and all-cause mortality without a prior atrial fibrillation diagnosis by any hypertensive disorder of pregnancy and individual subtypes.

		<u></u>			Exposure			
	Not Exposed	Any HDP	Gestational Hypertension	Chronic Hypertension	Preeclampsia	Superimposed Preeclampsia	Eclampsia	Unspecified
Incident Atrial	Fibrillation							
Total events	2,187	<300*	178	30	65	<10*	<10*	10
Total PY of follow-up	6,797,092	583,212	393,969	29,456	123,329	10,022	9,207	17,229
_{cs} IR per 10,000 PY (95% CI)	3.2 (3.1-3.3)	5.1 (4.6-5.6)	4.5 (4.0 - 5.1)	10.2 (7.1–13.2)	5.3 (4.2–6.4)	*	*	5.8 (2.8–8.8)
_{cs} IRR (95% CI)	Reference	1.58 (1.40–1.78)	1.40 (1.21–1.64)	3.17 (2.21–4.54)	1.64 (1.28–2.10)	*	*	1.80 (0.97–3.36)
All-cause Mort	ality without a	Prior Atrial Fib	villation Diagno	sis				
Total events	2,631	320	181	32	73	12	8	14
Total PY of follow-up	6,797,092	583,212	393,969	29,456	123,329	10,022	9,207	17,229
_{cs} IR per 10,000 PY (95% CI)	3.9 (3.8–4.0)	5.5 (5.0–6.0)	4.6 (4.0–5.2)	10.9 (7.7–14.0)	5.9 (4.8–7.1)	12.0 (6.3–17.7)	8.7 (3.6–13.7)	8.1 (4.6–11.7)
_{cs} IRR (95% CI)	Reference	1.42 (1.26–1.59)	1.19 (1.02–1.38)	2.81 (1.98–3.98)	1.53 (1.21–1.93)	3.09 (1.75–5.45)	2.24 (1.12–4.49)	2.10 (1.24–3.55)

891

892 Abbreviations: PY = person-years, CS= cause-specific, CI = confidence interval, IR = incidence rate, HR = hazard ratio

All calculations made using the fmsb package $(v.0.7.6)^{73}$ in RStudio (v. 2023.12.1.402).

* Data suppressed due to small numbers to comply with ICES privacy requirements

895

Table 3. Cause-specific multivariable adjusted hazard ratios (95% confidence intervals) for incident atrial fibrillation and allcause mortality without a prior atrial fibrillation diagnosis.


	Incident Atrial Fibrillation							
	Gestational Hypertension **	Preeclampsia	Eclampsia	Unspecified	Superimposed Preeclampsia	Chronic Hypertension in Pregnancy		
Adjusted* csHR (95% Cl)	1.49 (1.25-1.78)	1.53 (1.20-1.96)	1.55 (0.64-3.72)	1.66 (0.89-3.09)	1.70 (0.84-3.43)	2.24 (1.55-3.23)		
	All-Cause Mortality Without a Prior Atrial Fibrillation Diagnosis							
	Gestational Hypertension	Preeclampsia	Eclampsia	Unspecified	Chronic Hypertension in Pregnancy	Superimposed Preeclampsia		
Adjusted* csHR (95% Cl)	1.13 (0.97-1.31)	1.43 (1.13-1.81)	1.91 (0.95-3.82)	1.91 (1.13-3.23)	2.04 (1.43-2.91)	2.12 (1.20-3.78)		

899 Abbreviations: CS= cause-specific, CI = confidence interval

* All cause-specific hazard ratios adjusted for age at delivery, diabetes mellitus, polycystic ovary syndrome, sleep apnea, smoking,
 kidney disease, obesity, chronic immune-mediated conditions, and material resources (ON-Marg material resources dimension
 guintiles). Bolded estimates indicate statistical significance.

- 903 ** A time-segmented analysis was undertaken in these models whereby follow-up time for events was restricted to >4.5 years post 904 index delivery, as the PH assumption held for this follow-up period.
- 905
- 906
- 907
- 908
- 909

910 Figures



912 Figure 1. Flow diagram illustrating the selection of study subjects.

913

911

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition




Figure 2. Proportion of study subjects (per 1,000 deliveries) diagnosed with a hypertensive disorder of pregnancy during the study's exposure accrual period, by subtype. For each HDP subtype, the numerator included the total number of subjects diagnosed with that specific subtype during the study period and the denominator included the total number of study subjects.

921


915

922

923

```
Johnston et al. 2024
```

Original Research Article Submission: Go Red Special Edition



925

926 Figure 3. Median number of years to incident atrial fibrillation and all-cause mortality in

927 study subjects diagnosed with a hypertensive disorder of pregnancy, overall and by


928 exposure subtype.

929 Note: Results for eclampsia should be interpreted with caution due to the low number of events in 930

- subjects diagnosed with this HDP subtype (n < 10).
- 931
- 932

Johnston et al. 2024

Original Research Article Submission: Go Red Special Edition






934 Figure 4. Cause-specific cumulative incidence curves for atrial fibrillation (outcome) and

- 935 all-cause mortality (competing risk) stratified by hypertensive disorder of pregnancy
- 936 exposure status (first obstetrical delivery).

937



939 Figure 5. Cause-specific multivariable adjusted hazard ratios and accompanying 95% confidence intervals (log-scale), for

- 940 atrial fibrillation (A) and all-cause mortality (B) by any hypertensive disorder of pregnancy and each subtype.
- 941 Note: Hazard ratios adjusted for maternal age at delivery, diabetes mellitus, polycystic ovary syndrome, sleep apnea, smoking, kidney disease,
- 942 obesity, chronic immune-mediated conditions, and ON-Marg material resources dimension (quintiles).

943 Supplemental Material

- 944 Data Supplement S1-S8
- 945 Tables S1–S7
- 946 Figures S1-S5
- 947 References 1-22
- 948
- 949
- 950
- 951
- 952
- 953